Sero-epidemiological evaluation of malaria transmission in The Gambia before and after mass drug administration

Author details

Lindsey Wu[1], Julia Mwesigwa[2], Muna Affara[3], Mamadou Bah[2], Simon Correa[2], Tom Hall[4], James Beeson[5], Kevin K.A. Tetteh[1], Immo Kleinschmidt[6,7], Umberto D'Alessandro[2], Chris Drakeley[1]

1. London School of Hygiene and Tropical Medicine (LSHTM), Faculty of Infectious Tropical Diseases, Department of Infection Biology. London WC1E 7HT, UK.
2. Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine. Fajara, The Gambia.
3. Bernhard Nocht Institute for Tropical Medicine (BNITM). Arusha, Tanzania.
4. St. George's University of London (SGUL). SW17 0RE, London, United Kingdom.
5. Burnet Institute. Melbourne, Victoria, 3004, Australia.
6. London School of Hygiene and Tropical Medicine (LSHTM), Faculty of Epidemiology and Population Health, Department of Infectious Disease Epidemiology. London WC1E 7HT, UK.
7. School of Pathology, Wits Institute for Malaria Research, Faculty of Health Science, University of Witwatersrand. Johannesburg, South Africa.

Email addresses:

LW: lindsey.wu@lshtm.ac.uk

JM: julia.mwesigwa@lshtm.ac.uk

MA: affara@bnitm.de

MB: mmbah@mrc.gm

SC: scorrea@mrc.gm

TH: thall@sgul.ac.uk

JB: beeson@burnet.edu.au

KKAT: kevin.tetteh@lshtm.ac.uk

IK: immo.kleinschmidt@lshtm.ac.uk

UD: umberto.dalessandro@lshtm.ac.uk

CD: chris.drakeley@lshtm.ac.uk

Keywords: malaria, serology, mass drug administration, surveillance

Abstract: 200

Word count: 3,425

Abstract

Background

As The Gambia aims to achieve elimination by 2030, serological assays can be a useful surveillance tool to monitor trends in malaria incidence and evaluate community-based interventions.

Methods

Spatio-temporal variation in transmission in four Gambian study villages was measured using a panel of novel recombinant *Pf* antigens on a multiplexed bead-based serological assay. Village-level antibody levels were quantified as under-15 sero-prevalence, sero-conversion rates, and age-adjusted antibody acquisition rates. Antibody levels prior to mass drug administration (MDA) were assessed for their association with persistent malaria infection after community chemoprophylaxis.

Results

Seasonal changes in antibodies to Etramp5.Ag1 were observed in children under 15 in two transmission settings. At the end of the malaria season, short-lived antibody responses to Etramp5.Ag1, GEXP18, HSP40.Ag1, EBA175, and Rh2.2030 were higher amongst 1-15 year olds in the Upper River compared to the West Coast Region. Prior to MDA, individuals in the upper 50th percentile of above-average antibody levels in the dry season had two-fold higher odds of post-MDA clinical malaria during the transmission season.

Conclusions

Serological markers can serve dual functions as indicators of malaria exposure and incidence. Further studies, particularly cluster randomised trials, can help establish standardised serological protocols to measure transmission across endemic settings.

60 **Background**

61 Due to its pronounced seasonality and epidemiological landscape, The Gambia has a long history of
62 research on the heterogeneity of malaria in West Africa. Entomological and clinical data from the
63 late 1980s have shown spatial variation in malaria infections within just two kilometres of mosquito
64 breeding sites that were unexplained by bed-net use and entomological inoculation rates. It was
65 hypothesised that differences in effective immunity between households could be a driving factor in
66 variable patterns of clinical malaria.[1] There have also been landmark studies in The Gambia on
67 community-based interventions, including randomised trials demonstrating the impact on childhood
68 mortality and herd effects from insecticide-treated bed nets[2,3] and additional reductions in clinical
69 malaria when combined with chemoprophylaxis.[4] Subsequently, there have been rapid declines in
70 incidence through the scale-up of control interventions - improved diagnosis and treatment,
71 distribution of long-lasting insecticidal nets (LLINs), indoor residual spraying (IRS), and seasonal
72 malaria chemoprevention (SMC). However, micro-epidemiological variations in transmission
73 remain[5,6], which are increasingly relevant for the evaluation of interventions as The Gambia aims to
74 achieve malaria elimination by 2030.

75 Previous serological surveys in The Gambia have shown country-wide heterogeneities in malaria
76 transmission, including a 2012 school-based study where strong associations were observed
77 between sero-prevalence and microscopy-detectable parasitaemia.[7] More recent studies have since
78 identified new serological markers of *Plasmodium falciparum (Pf)* malaria exposure that have strong
79 correlations with clinical incidence in Uganda and Mali[8]. These antibody responses are a robust
80 measure of sero-incidence and could supplement existing surveillance tools to monitor transmission
81 and evaluate the effectiveness of community interventions.

82 In 2013, the Malaria Transmission Dynamics Study assessed epidemiological trends throughout the
83 malaria season (June – December) in six village pairs covering a range of transmission across The
84 Gambia.[5,6] In the following two years, annual rounds of mass drug administration (MDA) with

85 dihydroartemisnin-piperaquine (DHA-PQ) was also conducted between May and June, targeting
86 individuals aged 6 months to 75 years in all study villages.[9] Outcomes assessed included incidence of
87 clinical disease, prevalence of *Pf* infection measured by polymerase chain reaction (PCR), and factors
88 associated with infection post-MDA.

89 This study evaluates the use of antibody responses as a measure of malaria exposure and incidence
90 at the population level. Serological markers of malaria were used to measure spatio-temporal
91 variation in transmission in a subset of four study villages from the Malaria Transmission Dynamics
92 Study. A panel of novel recombinant *Pf* antigens were used to quantify population antibody levels
93 using a multiplexed immuno-assay. Village-level serological profiles were used to describe seasonal
94 and geographical variation in antibody responses and the association between antibody levels prior
95 to MDA and persistent malaria infection after community chemoprophylaxis was also estimated.

96 **Methods**

97 **Data and sampling**

98 A prospective cohort study was conducted from 2013 to 2015 in six village pairs across five
99 administrative regions - West Coast (WCR), North Bank (NBR), Lower River (LRR), Central River (CRR)
100 and Upper River (URR) Regions. *Pf* prevalence measured by PCR ranged from 2.27 to 19.60% in the
101 Central River and Upper River Regions respectively. As previously described by Mwesigwa et al,[6] the
102 study aim was to understand the dynamics of malaria infection and the impact of annual MDA.
103 Residents more than six months of age were enrolled in the study. Monthly surveys were conducted
104 during malaria transmission season (June to December) each year, in the dry season (April 2014),
105 and prior to the implementation of MDA (May and June). In both 2014 and 2015, one round of MDA
106 was conducted, with DHA-PQ administered to individuals aged 6 months and 75 years, according to
107 weight-based dosing guidelines, over 6 to 14 days between May and June in six pairs of study
108 villages.

109 Blood samples were collected by finger prick for haemoglobin measurement, blood smear for
110 malaria diagnosis by microscopy, and molecular and serological analysis by dried blood spot (DBS) on
111 filter paper (Whatman 3 Corporation, Florham Park, NJ, USA). Clinical malaria cases were identified
112 through passive case detection (PCD) at local health facilities or in villages by study nurses; clinical
113 malaria was defined as history of fever in the previous 24 hours or axillary temperature ≥ 37.5^{o}C and
114 a positive rapid diagnostic test (RDT) result (Paracheck *Pf*, Orchid Biomedical System, India).

115 Serological analysis included all available samples from the WCR in Besse and N'Demban from
116 surveys conducted at the start of the transmission season in July 2013 (N=537) and at the end of the
117 season in December 2013 (N=526). In the URR, analysis included all samples collected in Njaiyal and
118 Madino Samako in July 2013 (N=779), December 2013 (N=632), April (dry season) 2014 (N=823), and
119 December 2014 (N=757). These regions represent extremes of two transmission intensities, with
120 months selected at the start and end of the transmission season. Samples from clinical PCD cases
121 were linked by study participant identification code to samples from the same individuals collected
122 during routine monthly surveys. Samples collected as part of the Malaria Transmission Dynamics
123 Study and subset of samples for serological analysis are described in Supplementary Figure 1.

124 **Laboratory procedures**

125 A full description of laboratory methods is detailed in Wu et al[10] and Mwesigwa et al[11]. Briefly, serum
126 samples were eluted from 6mm DBS (4 µL whole blood equivalent) and prepared as a 1:500 dilution.
127 Two wells on each plate containing only antigen-coupled beads and sample buffer were included to
128 measure background signal. A pool of 22 serum samples from malaria hyper-immune individuals in
129 The Gambia were used as positive controls in a 6-point 5-fold serial dilution (1:10 – 1:31,250) and
130 plasma samples from European malaria-naive adults (1:500 dilution) as negative controls. Serum
131 samples were processed on the Luminex MAGPIX, with mean fluorescence intensity (MFI) values
132 between plates normalised according to the protocol described in Wu et al 2019.[12]

133 For diagnostic PCR, DNA was extracted from three 6-mm DBS (4 µL whole blood equivalent) using
134 the automated QIAxtractor robot (Qiagen). Negative and positive (3D7) controls were included to
135 control for cross contamination and DNA extraction efficiency, respectively. Extracted DNA was used
136 in a nested PCR, amplifying multi-copy *Plasmodium* ribosomal RNA gene sequences using genus and
137 species-specific primers. All PCR products were run using the QIAxcel capillary electrophoresis
138 system (Qiagen).

139 **Statistical analyses**

140 Antibody responses were summarised at village level and used to describe geographical differences
141 in transmission between the West Coast (low transmission) and Upper River Regions (moderate-high
142 transmission). Temporal changes within each region were assessed using village-level antibody
143 response during the malaria transmission season (July and December 2013) and in the subsequent
144 dry season (April 2014). Population antibody responses were represented in several ways as
145 summarised below.

146 ***Sero-prevalence and sero-conversion rate.*** For antigens associated with longer lived antibody
147 responses - *P.falciparum* merozoite surface antigen 1 19-kDa carboxy-terminal region (*Pf*MSP1$_{19}$)
148 and *P.falciparum* apical membrane antigen 1 (*Pf*AMA1), the distribution of MFI for all serological
149 samples in the study was characterised through a two-component Gaussian mixture model to define
150 distributions of negative and positive antibody levels. The sero-positivity threshold was defined as
151 the mean log MFI values plus two standards deviations of the negative distribution.[13] Mixture
152 models were estimated using the '*normalmixEM'* function in the *'mixtools'* package v1.0.4 in R
153 version 3.6.1. For antigens associated with shorter-lived antibodies where statistical evidence of a
154 bimodal distribution of antibody responses in the population is not strong – early transcribed
155 membrane protein 5 (Etramp5.Ag1), gametocyte export protein 18 (GEXP18), heat shock protein 40
156 (HSP40.Ag1), erythrocyte binding antigen 175 RIII-V (EBA175), reticulocyte binding protein

157 homologue 2 (Rh2.2030) - the sero-positivity threshold was defined by the mean log MFI plus three
158 standard deviations of 71 malaria-naïve European blood donors used as negative controls.

159 Age-adjusted sero-conversion rates (SCRs), the rate at which sero-negative individuals become sero-
160 positive per year, were estimated for antigens associated with long-lived antibody response
161 (*Pf*MSP1$_{19}$, *Pf*AMA1). A reversible catalytic model was fitted to age-adjusted sero-positivity data
162 using maximum likelihood methods.[14] A common sero-reversion rate for each antigen was assumed
163 across all villages, which was estimated based on fitting a single sero-catalytic model to all
164 individuals in the sample and fixing the sero-reversion rate to this value in all subsequent village-
165 specific model fits. Models were fit for each antigen, and SCRs estimated separately for each village
166 and survey month.

167 In addition to sero-conversion rates based on all ages, sero-prevalence for all antigens was
168 estimated specifically for children aged 1-15 years. Individuals in this age range are less likely to have
169 high levels of long-lived antibodies from previous malaria exposure and antibodies are more likely to
170 reflect recent infection. Sero-prevalence based on this age group may also have relevance for
171 school-based surveys and interventions.[7,15]

172 ***Age-dependent antibody acquisition.*** Antibody acquisition models[16,17] were used to estimate age-
173 dependent changes in antibody levels. Geometric mean MFI values were calculated for defined age
174 groups and used to estimate antibody acquisition rates for each antigen, by village, and by monthly
175 survey. Two variants of the model were used – one assuming that geometric mean antibody levels
176 increase at a constant rate with age and the second assuming that different antibody acquisition
177 rates for two distinct age groups (described further in the Supplementary Methods). Area Under the
178 Antibody Acquisition Curve (AUC) values were calculated based on the model fit for each village and
179 survey month, representing the cumulative antibody intensity across all ages in the population at
180 that time.[18] Antibody levels were compared between seasons within regions (URR and WCR) and
181 between regions for the same season. Strength of evidence for observed differences are presented

182 as p-values, derived by comparing the posterior distributions of predicted antibody levels over a
183 specified age range (i.e., all-ages or 1-15 years).

184 ***Dry season antibody levels and odds of infection post-MDA.*** Individual antibody levels in the dry
185 season (April) prior to the implementation of MDA were assessed by comparing observed and
186 expected MFI value as predicted by the age-adjusted antibody acquisition model fit for all individuals
187 in URR-South in April 2014. For individuals with above average MFI values for their age group, the
188 difference between observed and expected logMFI was calculated and classified to either below or
189 above median of residual MFI antibody response. Logistic regression was used to estimate the odds
190 of clinical malaria (passively detected via the health facility or study nurses in the community) or
191 asymptomatic *Pf* infection (actively detected using PCR from monthly survey samples) during the
192 transmission season following MDA (October – December 2014) amongst individuals below and
193 above median residual dry season antibody levels, compared to individuals at or below expected
194 antibody responses, allowing for clustering at the household/compound. Multivariate analyses also
195 adjusted for age, LLIN use, and MDA adherence using generalised linear mixed-effects models with
196 the 'glm' and 'glmer' functions in the 'lme4' v1.1-21 package in R version 3.6.1.

197 **Results**

198 ***Sero-prevalence in children by geographical region and transmission season.*** Variation in sero-
199 prevalence between geographical region and transmission season differed by antigen. More
200 specifically, differences in sero-prevalence to Etramp5.Ag1 and GEXP18 were observed between July
201 (start of the transmission season) and December (end of the transmission season) in children aged 1-
202 15 years in the West Coast Region (Table 1, Supplementary Figure 1). In the URR, there was
203 statistically strong evidence for differences between July and December for nearly all antigens, with
204 moderate statistical evidence for GEXP18. No significant decline in sero-prevalence was observed
205 between December 2013 and April 2014 for any antigen in either region.

206 ***Sero-conversion rate between geographical regions and transmission seasons.*** Differences in SCR
207 between geographical region and transmission season also varied by antigen (Figures 1 and 2,
208 Supplementary Table 1). In the West Coast Region, changes in antibody responses between
209 transmission seasons were larger for *Pf*MSP1$_{19}$ (0.0147 increase in SCR between July and December)
210 compared to *Pf*AMA1 (0.0007 increase in SCR). In the Upper River Region, seasonal differences
211 between July and December 2013 for both antigens were larger than the West Coast Region, with an
212 increase in *Pf*MSP1$_{19}$ SCR of 0.0405 and increase of 0.0301 in *Pf*AMA1 SCR. There was no significant
213 change in SCR between December 2013 and April 2014 for either antigen.

214 At the start of the malaria transmission season (July 2013), *Pf*MSP1$_{19}$ SCR was twice as high in the
215 Upper River Region (SCR 0.0130, 95%CI 0.0088 – 0.0194) compared to the West Coast Region (SCR
216 0.0067, 95%CI 0.0037 – 0.0123). After peak transmission season, this difference was more
217 pronounced, with *Pf*MSP1$_{19}$ SCR 0.0214 (95%CI 0.0087 – 0.0530) in the West Coast Region compared
218 to SCR 0.0535 (95%CI 0.0344 – 0.0831) in the Upper River Region. *Pf*AMA1 SCR in the Upper River
219 Region was consistently higher than the West Coast Region throughout the transmission season,
220 with SCR 0.0159 (95%CI 0.0080 – 0.0239) and 0.0614 (95%CI 0.0509 – 0.0740) for the West Coast
221 and Upper River Regions, respectively, in July, and SCR 0.0166 (95%CI 0.0124 – 0.0224) and 0.0915
222 (95%CI 0.0738 – 0.1135) in the West Coast and Upper River Regions, respectively, in December.
223 Increases in sero-prevalence in older age groups are not pronounced for markers associated with
224 short-lived antibody responses, which is an underlying assumption when using sero-catalytic models.
225 Therefore, antibody acquisition models are used to assess age-adjusted changes in antibody
226 responses based on continuous data for markers of short-lived antibody responses.

227 ***Age-adjusted antibody acquisition by geographical region and transmission season.*** For antigens
228 associated with long-lived antibody responses (*Pf*MSP1$_{19}$ and *Pf*AMA1), differences in age-adjusted
229 antibody acquisition were observed between the West Coast and Upper River Regions at the end of
230 the transmission season (December 2013) (Supplementary Figures 5 and 6, Supplementary Tables

231 S7-S8). For *Pf*MSP1$_{19,}$ differences in geometric mean antibody levels in children aged 1-15 years in
232 the Upper River Region were higher at the end of the transmission season compared to the start of
233 the season (p=0.025). Additionally, higher antibody levels to *Pf*AMA1 in 1-15 year olds were
234 observed in the Upper River Region compared to the West Coast Region at the end of the
235 transmission season (p<0.001). No significant differences in antibody levels for *Pf*AMA1 were
236 observed between the start and end of transmission season in the Upper River Region.

237 In contrast to *Pf*MSP1$_{19}$ and *Pf*AMA1, all serological markers associated with shorter-lived antibody
238 responses (Etramp5.Ag1, GEXP18, HSP.Ag1, EBA175, and Rh2.2030) showed higher antibody levels in
239 1-15 year olds in the Upper River Region compared to the West Coast Region at the end of the
240 transmission season (Figures 3-5, Supplementary Figures 3 and 4, Supplementary Tables 2-6). In the
241 Upper River Region, there were higher antibody responses to Etramp5.Ag1 at the end of the
242 transmission season amongst individuals aged 1-15 years (p=0.001). However, antibody levels in 1-
243 15 year olds for HSP40.Ag1 were lower at the end of the transmission season in the West Coast
244 Region (p=0.004). At the start of the transmission season, antibody levels to GEXP18 were higher in
245 the Upper River compared to the West Coast Region (p=0.032). There were no within-region
246 differences in antibody responses between the dry season (April 2014) and the transmission season
247 (December 2013 and 2014) for any of the antigens tested.

248 ***Association between pre-MDA antibody levels and post-MDA malaria infection.***

249 After adjusting for age, LLIN use in the last 24 hours, and MDA compliancy, individuals in the upper
250 50th percentile of above-average antibody levels to Etramp5.Ag1 for their age group in the dry
251 season (April 2014, before the implementation of MDA) had two-fold higher odds of clinical malaria
252 (aOR 1.91 95%CI 1.053– 3.52, p=0.039) in the transmission season (October – December 2014) after
253 MDA (Figure 6A, Supplementary Table 9). Dry season antibody levels to Rh2.2030 were also
254 moderately associated with increased odds of clinical malaria (OR 1.75 95%CI 0.93 – 3.30, p=0.085)
255 after MDA (Figure 6A, Supplementary Table 13), but statistical evidence was not strong. Similarly,

256 there was a borderline association between above average antibody levels to *Pf*AMA1 in the dry
257 season and increased odds of clinical malaria (OR 1.70 95%CI 0.97 – 2.98, p=0.065) but statistical
258 association was weak after adjusting for age, LLIN use and MDA compliancy (Figures 6A,
259 Supplementary Table 15). Antibody responses to all other antigens investigated were not associated
260 with increased odds of infection post-MDA (Supplementary Tables 10-14).

261 **Discussion**

262 This study investigated a range of indicators characterising population-level antibody responses.
263 Spatio-temporal variations in serological responses were observed for several *P.falciparum* antigens.
264 There were seasonal differences in sero-prevalence for nearly all antigens in the higher transmission
265 setting (Upper River Region) as well as in the low transmission West Coast Region (Etramp5.Ag1 and
266 GEXP18) amongst children aged 1-15 years. These differences likely reflect a combination of changes
267 in malaria incidence as well residual antibodies from prior infection. In moderate to high
268 transmission settings, higher antibody levels amongst older children in the dry season is common,
269 where immunity to clinical malaria is acquired after 10 to 15 years of exposure.[19,20] Children in this
270 age range may be a useful sentinel population to monitor transmission in school-based surveys. This
271 could also be used to evaluate the effectiveness of malaria control interventions or identify areas at
272 risk of increased clinical incidence. It is important to note that nearly all malaria indicators or survey
273 designs are associated with a degree of bias that may result in underestimation of transmission. For
274 example, school surveys may be less appropriate in South East Asia where the age distribution of
275 malaria differs to sub-Saharan Africa. Serological surveillance protocols should therefore be
276 designed to align or be combined with other routine measures of transmission.

277 Differences in sero-conversion rates to *Pf*MSP1$_{19}$ and *Pf*AMA1 were observed between geographical
278 regions but not between transmission seasons in the same region. Long-lived antibody responses
279 likely reflect past malaria exposure rather than short-term changes in sero-incidence within a single
280 transmission season and statistical methods to confirm differences in sero-conversion rates still

281 require harmonisation between researchers. However, these markers have been shown to be
282 sensitive to changes in transmission over longer periods of time in The Gambia.[21] Antibody
283 acquisition models can detect more subtle differences in the magnitude of antibody levels,
284 particularly for antigens associated with short-lived antibody responses. All five of the novel sero-
285 incidence markers evaluated in this study - Etramp5.Ag1, GEXP18, HSP40.Ag1, EBA175, and
286 Rh2.2030 - detected geographical differences in antibody acquisition. Additionally, a subset of these
287 markers (Etramp5.Ag1 and HSP40.Ag1) were also able to detect seasonal differences in high and low
288 transmission settings.

289 Between December 2013 and April 2014, antibody levels did not decline significantly for any
290 antigens except GEXP18, indicating that antibody decay at the population level likely occurs over a
291 period longer than four months. This may be due to persistent parasitaemia in asymptomatic
292 individuals or infections occurring late in the transmission season in December. While findings are
293 based on limited timepoints, several longitudinal studies in The Gambia have observed measurable
294 antibody decay in children in the dry season against antigens associated with protective
295 immunity.[22,23] Similar studies in Mali have quantified antibody responses to over 2,000 *P.falciparum*
296 antigens on protein microarray before and after the malaria season and observed rapid declines in
297 children under 10 within six months of the end of the transmission season.[24] Further research to
298 estimate the longevity of antibody responses across all ages could help determine optimal sampling
299 timeframes (and populations) for future serological surveillance.

300 Above average antibody levels in the dry season before MDA were associated with increased odds of
301 clinical malaria following MDA. Associations were moderate for Rh2.2030 and *Pf*AMA1, but
302 individuals with higher than average antibody levels against Etramp5.Ag1 had a two-fold higher odds
303 of clinical malaria post-MDA. Similar associations were also observed with parasitological endpoints,
304 as previously reported by Mwesigwa et al, where individuals with *P.falciparum* infection (detected
305 by PCR) in the dry season had increased odds of re-infection during the post-MDA transmission

306 season.[9] This study was not designed to assess the effectiveness of MDA using serological endpoints,
307 so sample size may not be adequately powered to draw strong conclusions. However, it is possible
308 that assessing serological responses in different months, where sampling frequency is informed by
309 antibody boost and decay rates, could provide more accurate information. Analysis of a larger set of
310 antigens or grouping antibody data based on antigen expression or function during the parasite life
311 cycle may help delineate the wide range of responses with respect to malaria exposure, incidence,
312 or immunity. Studies measuring persistent asymptomatic parasitaemia throughout the dry and wet
313 seasons would also further elucidate the dynamics between parasite density, immunity, and
314 serological response.

315 This study has demonstrated that a large number of new serological markers of malaria can be
316 optimised for high throughput use on an affordable immuno-assay platform. Findings also show the
317 duality of using a diverse serological panel of markers to monitor malaria exposure (observed
318 through long-lived antibody responses) and malaria incidence (observed through shorter-lived
319 antibody responses). Extension of this research to larger studies, particularly cluster randomised
320 trials, can help to establish standardised serological protocols for measuring transmission for use
321 across a variety of epidemiological settings.

322 **List of abbreviations**

323 aOR: Adjusted odds ratio
324 AUC: Area Under the Antibody Acquisition Curve
325 CI: Confidence interval
326 DBS: Dried blood spot
327 DHA-PQ: Dihydroartemisnin-piperaquine
328 EBA175: Erythrocyte binding antigen 175 RIII-V
329 Etramp5.Ag1: Early transcribed membrane protein 5
330 GEE: Generalised estimating equations
331 GEXP18: Gametocyte export protein 18 (GEXP18)
332 HSP40.Ag1: Heat shock protein 40

333 IgG: Immunoglobulin

334 LLIN: Long-lasting insecticide treated net

335 MDA: Mass drug administration (MDA)

336 MFI: Median fluorescence intensity

337 PCD: Passive case detection

338 PCR: Polymerase chain reaction

339 *Pf, P.falciparum*: *Plasmodium falciparum*

340 *Pf*AMA1: *P.falciparum* apical membrane antigen 1

341 *Pf*MSP1$_{19}$: *P.falciparum* merozoite surface antigen 1 19-kDa carboxy-terminal region

342 RDT: Rapid diagnostic test

343 Rh2.2030: Reticulocyte binding protein homologue 2

344 SCR: Sero-conversion rate

345 URR: Upper River Region, The Gambia

346 WCR: West Coast Region, The Gambia

347

348 **Ethics approval and consent to participate**

349 This study was approved by the Gambia Government/MRC Joint Ethics Committee (SCC1318). Verbal
350 consent was first obtained at village sensitisation meetings, followed by individual written informed
351 consent for all participants. Parents/guardians provided written consent for children less than
352 17 years, and assent was obtained from children between 12 and 17 years.

353 **Competing interests**

354 All authors declare no competing interests.

355 **Funding**

356 This work was supported by the UK Medical Research Council (UKMRC) through the LSHTM Doctoral
357 Training Programme studentship received by LW. The funders had no role in the design of the study,
358 collection, analysis, interpretation of data or writing of the manuscript.

359 **Corresponding author**

360 Lindsey Wu

361 London School of Hygiene and Tropical Medicine

362 Faculty of Infectious and Tropical Diseases

363 Department of Infection Biology

364 Keppel Street

365 London

366 WC1E 7HT

367 +44 (0) 797 243 5577

368 lindsey.wu@lshtm.ac.uk

369 **References**

370 1. Thomas, C. J. & Lindsay, S. W. Local-scale variation in malaria infection amongst rural
371 Gambian children estimated by satellite remote sensing. *Trans. R. Soc. Trop. Med. Hyg.* **94**,
372 159–63

373 2. D'Alessandro, U. *et al.* Mortality and morbidity from malaria in Gambian children after
374 introduction of an impregnated bednet programme. *Lancet* **345**, 479–483 (1995).

375 3. Snow, R. W., Rowan, K. M., Lindsay, S. W. & Greenwood, B. M. A trial of bed nets (mosquito
376 nets) as a malaria control strategy in a rural area of The Gambia, West Africa. *Trans. R. Soc.*
377 *Trop. Med. Hyg.* **82**, 212–5 (1988).

378 4. Alonso, P. L. *et al.* A malaria control trial using insecticide-treated bed nets and targeted
379 chemoprophylaxis in a rural area of The Gambia, West Africa: 6. The impact of the
380 interventions on mortality and morbidity from malaria. *Trans. R. Soc. Trop. Med. Hyg.* **87**, 37–
381 44 (1993).

382 5. Mwesigwa, J. *et al.* On-going malaria transmission in The Gambia despite high coverage of
383 control interventions: a nationwide cross-sectional survey. *Malar. J.* **14**, 314 (2015).

384 6. Mwesigwa, J. *et al.* Residual malaria transmission dynamics varies across The Gambia despite
385 high coverage of control interventions. *PLoS One* **12**, e0187059 (2017).

386 7. Okebe, J. *et al.* School-Based Countrywide Seroprevalence Survey Reveals Spatial
387 Heterogeneity in Malaria Transmission in the Gambia. *PLoS One* **9**, e110926 (2014).

388 8. Helb, D. A. *et al.* Novel serologic biomarkers provide accurate estimates of recent
389 Plasmodium falciparum exposure for individuals and communities. *Proc. Natl. Acad. Sci. U. S.*
390 *A.* **112**, E4438-47 (2015).

391 9. Mwesigwa, J. *et al.* Mass Drug Administration With Dihydroartemisinin-piperaquine and
392 Malaria Transmission Dynamics in The Gambia: A Prospective Cohort Study. *Clin. Infect. Dis.*
393 **69**, 278–286 (2019).

394 10. Wu, L. *et al.* Optimisation and standardisation of a multiplex immunoassay of diverse

395 Plasmodium falciparum antigens to assess changes in malaria transmission using sero-
396 epidemiology. *Wellcome Open Res.* **4**, 26 (2019).
397 11. Snounou, G. Genotyping of Plasmodium spp. Nested PCR. *Methods Mol. Med.* **72**, 103–116
398 (2002).
399 12. Wu, L. *et al.* Optimisation and standardisation of a multiplex immunoassay of diverse
400 Plasmodium falciparum antigens to assess changes in malaria transmission using sero-
401 epidemiology. *Wellcome Open Res.* **4**, 26 (2019).
402 13. Stewart, L. *et al.* Rapid assessment of malaria transmission using age-specific sero-conversion
403 rates. *PLoS One* **4**, e6083 (2009).
404 14. Drakeley, C. J. *et al.* Estimating medium- and long-term trends in malaria transmission by
405 using serological markers of malaria exposure. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 5108–13
406 (2005).
407 15. Stevenson, J. C. *et al.* Reliability of School Surveys in Estimating Geographic Variation in
408 Malaria Transmission in the Western Kenyan Highlands. *PLoS One* **8**, e77641 (2013).
409 16. Weber, G. E. *et al.* Sero-catalytic and Antibody Acquisition Models to Estimate Differing
410 Malaria Transmission Intensities in Western Kenya. *Sci. Rep.* **7**, (2017).
411 17. Yman, V. *et al.* Antibody acquisition models: A new tool for serological surveillance of malaria
412 transmission intensity. *Sci. Rep.* **6**, 19472 (2016).
413 18. Arnold, B. F. *et al.* Measuring changes in transmission of neglected tropical diseases, malaria,
414 and enteric pathogens from quantitative antibody levels. *PLoS Negl. Trop. Dis.* **11**, e0005616
415 (2017).
416 19. Carneiro, I. *et al.* Age-Patterns of Malaria Vary with Severity, Transmission Intensity and
417 Seasonality in Sub-Saharan Africa: A Systematic Review and Pooled Analysis. *PLoS One* **5**,
418 e8988 (2010).
419 20. Griffin, J. T., Ferguson, N. M. & Ghani, A. C. Estimates of the changing age-burden of
420 Plasmodium falciparum malaria disease in sub-Saharan Africa. *Nat. Commun.* **5**, 3136 (2014).

421 21. van den Hoogen, L. L. *et al.* Serology describes a profile of declining malaria transmission in
422 Farafenni, The Gambia. *Malar. J.* **14**, 416 (2015).
423 22. Akpogheneta, O. J. *et al.* Duration of Naturally Acquired Antibody Responses to Blood-Stage
424 Plasmodium falciparum Is Age Dependent and Antigen Specific. *Infect. Immun.* **76**, 1748–1755
425 (2008).
426 23. White, M. T. *et al.* Dynamics of the Antibody Response to Plasmodium falciparum Infection in
427 African Children. *J. Infect. Dis.* **210**, 1115–1122 (2014).
428 24. Crompton, P. D. *et al.* A prospective analysis of the Ab response to Plasmodium falciparum
429 before and after a malaria season by protein microarray. *Proc. Natl. Acad. Sci. U. S. A.* **107**,
430 6958–63 (2010).
431
432
433

434 **Table 1. Sero-prevalence in children aged 1-15 years by antigen, geographical region, and transmission season.** Mean estimate of sero-prevalence is
435 shown as percentage, with 95% confidence interval shown in parentheses.

	*Pf*MSP1$_{19}$	*Pf*AMA1	Etramp5.Ag1	Rh2.2030	EBA175	GEXP18	HSP40.Ag1
West Coast Region							
July 2013 (n=314)	3.5% (1.5 - 5.5)	7.0% (4.2 - 9.8)	6.1% (3.4 - 8.7)	1.4% (0.0 - 3.1)	1.9% (0.1 - 3.8)	12.6% (8.0 – 17.1)	6.3% (3.0 - 9.6)
Dec 2013 (n=317)	8.2% (5.1 – 11.2)	6.9% (4.1 – 9.7)	13.6% (9.8 – 17.3)	3.5% (1.5 – 5.5)	1.9% (0.4 – 3.4)	16.4% (12.3 – 20.5)	7.9% (4.9 – 10.9)
Upper River Region							
July 2013 (n=437)	5.9% (3.7 – 8.2)	25.6% (21.5 – 29.7)	9.8% (7.0 – 12.6)	12.1% (9.1 – 15.2)	9.6% (6.8 – 12.4)	28.8% (24.6 – 33.1)	13.0% (9.9 – 16.2)
Dec 2013 (n=390)	20.8% (16.7 – 24.8)	36.7% (31.9 – 41.4)	30.3% (25.7 – 34.8)	27.9% (23.5 – 32.4)	17.4% (13.7 – 21.2)	36.7% (31.9 – 41.4)	23.8% (19.6 – 28.2)
Apr 2014 (n=504)	14.7% (11.6 – 17.8)	31.7% (27.7 – 35.8)	23.8% (20.1 – 27.5)	23.6% (19.9 – 27.3)	15.5% (12.3 – 18.6)	35.1% (31.0 – 39.3)	24.4% (20.7 – 28.2)
Dec 2014 (n=449)	16.0% (12.6 – 19.4)	31.0% (26.7 – 35.2)	26.9% (22.8 – 31.1)	22.9% (19.1 – 26.8)	14.9% (11.6 – 18.2)	43.9% (39.3 – 48.5)	28.3% (241. – 32.5)

436 **Figure 1. *Pf*MSP1.19 sero-conversion rates by transmission season and geographical region.** Mean
437 and 95% confidence intervals of sero-prevalence for each age group are shown as circles and vertical
438 lines, respectively. Mean fit of the reverse catalytic model is shown as a solid line for the end of the
439 transmission season (December) and dotted line for the dry season (April) or start of the
440 transmission season (July). Shaded regions are the 95% confidence interval of the model fit



441

442 **Figure 2. *Pf*AMA1 sero-conversion rates by transmission season and geographical region.** Mean
443 and 95% confidence intervals of sero-prevalence for each age group are shown as circles and vertical
444 lines, respectively. Mean fit of the reverse catalytic model is shown as a solid line for the end of the
445 transmission season (December) and dotted line for the dry season (April) or start of the
446 transmission season (July). Shaded regions are the 95% confidence interval of the model fit



447
448
449
450
451
452
453
454

455 **Figure 3. Age-dependent antibody acquisition for Etramp5.Ag1 by geographical region and**
456 **transmission season.** Mean and 95% confidence intervals of geometric mean antibody levels for
457 each age group are shown as circles and vertical lines, respectively. Median fit of the antibody
458 acquisition model is shown as a solid line for the end of the transmission season (December) and
459 dotted line for the dry season (April) or start of the transmission season (July). Shaded regions are
460 the 95% credible intervals of the model fit.



461

462 **Figure 4. Age-dependent antibody acquisition for GEXP18 by geographical region and transmission**
463 **season.** Mean and 95% confidence intervals of geometric mean antibody levels for each age group
464 are shown as circles and vertical lines, respectively. Median fit of the antibody acquisition model is
465 shown as a solid line for the end of the transmission season (December) and dotted line for the dry
466 season (April) or start of the transmission season (July). Shaded regions are the 95% credible
467 intervals of the model fit.



468
469
470
471
472
473

Figure 5. Age-dependent antibody acquisition for HSP40.Ag1 by geographical region and transmission season. Mean and 95% confidence intervals of geometric mean antibody levels for each age group are shown as circles and vertical lines, respectively. Median fit of the antibody acquisition model is shown as a solid line for the end of the transmission season (December) and dotted line for the dry season (April) or start of the transmission season (July). Shaded regions are the 95% credible intervals of the model fit.



498 **Figure 6. Association of pre-MDA dry season antibody levels and odds of clinical malaria (a) or**
499 **asymptomatic infection (b) during transmission season post-MDA.** Odds ratios are adjusted for age,
500 LLIN use and MDA compliancy. Clinical malaria is defined as clinical or RDT confirmed case,
501 asymptomatic infection is defined as PCR-positive and clinically or RDT-negative.



502



503

504